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ABSTRACT
New pathway databases generally display pathways
by retrieving information from a database dynamic-
ally. Some of them even provide their pathways in
SBML or other exchangeable formats. Integrating
these models is a challenging work, because these
models were not built in the same way. Pathways
integration Tool (PINT) may integrate the standard
SBML files. Since these files may be obtained from
different sources, any inconsistency in component
names can be revised by using an annotation editor
upon uploading a pathway model. This integration
function greatly simplifies the building of a complex
model from small models. To get new users started,
about 190 curated public models of human
pathways were collected by PINT. Relevant models
can be selected and sent to the workbench by using
a user-friendly query interface, which also accepts a
gene list derived from high-throughput experiments.
The models on the workbench, from either a public
or a private source, can be integrated and painted.
The painting function is useful for highlighting im-
portant genes or even their expression level on a
merged pathway diagram, so that the biological sig-
nificance can be revealed. This tool is freely avail-
able at http://csb2.ym.edu.tw/pint/.
INTRODUCTION
Public-domain pathway models have become an invalu-
able resource to the research community. Hundreds of
expert-curated biological pathways are available in the
public domain databases (1–3). Unlike conventional
pathways that were purely static diagrams, many of
these pathways have been prepared as text-based models
in machine-readable formats such as Systems Biology
Markup Language (SBML) (4) and Biological Pathways
eXchange (BioPax) (http://www.biopax.org). These
formats have been tailored to facilitate data storage and
exchange as well as information retrieval, thus rendering
high accessibility to pathway models. A number of
pathway tools have therefore been designed to take ad-
vantage of pathway models to perform pathway analysis
such as topological network analysis and mathematical
simulation (5). Besides, bench biologists may use visual-
ization tools to map data on top of the diagrams of such
models to aid the interpretation of experiment results
(6–8).
One issue concerning the application of public-domain
pathway models is that each such model usually contains
just partial information about the biological networks,
covering only a subset of molecules that are implicated
in a cellular response to stimuli. A plausible situation
that biologists may encounter is that phenotypically
relevant entities screened from high-throughput experi-
ments may disperse across distinct pathway models. This
means that, when investigating how such entities contrib-
ute to a phenotype, biologists may have to jump back and
forth among several pathway diagrams to look for reac-
tions participated by these entities. This process demands
considerable eﬀort and can be error-prone. We argue that
one approach to improve this situation is to integrate
multiple pathway models together to build a more com-
prehensive one. In the following text, we refer to this op-
eration as biological pathways integration (BPI).
BPI is more than a trick to build bigger models. New
models created through BPI may beneﬁt biologists on
several occasions. For instance, novel protein–protein
interactions may suggest crosstalk among initially
distinct pathway models (9); fusion genes in cancer cells
may result in aberrant function links among normally in-
dependent pathways (10,11); promiscuous domains in
certain cancer proteins may mediate abnormal protein–
protein interactions (12), possibly leading to pathological
pathway crosstalk; a therapeutic agent targeting against
one malignant pathway might have failed due to yet
*To whom correspondence should be addressed. Tel: +886 2 2826 7128; Fax: +886 2 2825 0480; Email: yang@ym.edu.tw
The authors wish it to be known that, in their opinion, the ﬁrst two authors should be regarded as joint First Authors.
W124–W131 Nucleic Acids Research, 2010, Vol. 38, Web Server issue Published online 10 June 2010
doi:10.1093/nar/gkq499
 The Author(s) 2010. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.unconﬁrmed crosstalk from other pathways to compen-
sate the blocked function (13). In either case mentioned
above, a merged model of potentially associated pathways
may provide a better overview of all implicated and sus-
picious entities—the ﬁrst step toward interpreting bio-
logical observations.
Currently, BPI is not really supported by most
public-domain pathway editors. Most such tools only
permit entities to be added/deleted one by one, namely
in an incremental manner. Albeit a general ‘copy and
paste’ operation may place the topological structures of
more than one pathway together, it cannot rebuild the
relations among distinct models. SemanticSBML is the
only tool we are aware that supports pathways integra-
tion. However, this tool appears to have been designed for
experienced curators who are familiar with a number of
entity annotation systems (14). Besides, installing the
standalone version of this tool in a local machine is very
diﬃcult. Here, we present Pathways Integration Tool,
PINT, a website that is free and open to all users and
there is no login and installation requirement, to facilitate
BPI. Our website was designed to make BPI a less painful
task, not assuming that new users must know where to
ﬁnd useful pathway models to start an integration, what
the diﬀerence is between various notation conventions,
and how to ﬁnd the UniProt or ChEBI accession
numbers for entities. Besides, the PINT painting
function can highlight particular entities on a merged
diagram. We describe in the following sections about the
implementation and the unique features of PINT. We also
show an application of PINT to explore the features of
cancer related pathways.
IMPLEMENTATION
The main subject of BPI is about how multiple pathway
models can be integrated to generate a merged model, in
which not only the original pathway information in each
model is preserved but also the initially unavailable
inter-pathway relations can be rebuilt. Hence, PINT has
been implemented with a set of functions to assist users to
ﬁnish the following steps: (i) users upload their pathway
models into a BPI system; (ii) the BPI system pool users’
pathway models together; (iii) the BPI system ﬁnds
pairwise relation among pathway models; (iv) the BPI
system rebuilds the inter-model connections; and (v) the
BPI system removes the redundant nodes and edges from
the merged model. In particular, PINT provides two
useful features, a tolerant integration mode and an
online annotation editor, to help manage the exceptions
caused by the inter-model incompatibilities of the annota-
tion styles and data storage formats, respectively. The
PINT rule and core functions used to integrate pathways
are further described in the following sections.
The pathways integration rule
In the process of integrating pathway models, the ﬁrst
step, perhaps the most important one, is to ﬁnd the ‘rela-
tions’ among the models to be integrated. In the PINT
BPI function, the concurrent occurrences of an entity
across distinct models are considered as an inter-pathway
relation. PINT takes such entities to be a putative ‘linker’
that can re-connect two initially distinct models.
PINT integrates multiple pathway models into a merged
one through a process involving identiﬁcation of candi-
date linkers among models and reconstruction of relations
between initially distinct models (Figure 1A and B).
Technically, PINT integrates pathways at the level of
nodes, which may consist of one or multiple entities (i.e.
a complex). To ensure that a merged model can convey
accurate biological information, PINT employs a strin-
gent rule to perform BPI. For integrating pathways P1
and P2, as in Figure 1A, PINT uses the following
criteria to determine if nodes N1 and N2 can be linkers:
(i) Node N1 is in the same compartment as node N2.
(ii) Node N1 consists of exactly the same set of entities
as node N2 does.
(iii) Entities considered to be identical are annotated
with exactly the same properties (e.g. symbols, ac-
cession numbers and modiﬁcations).
Thus, nodes N1 and N2 as a whole is a putatively iden-
tical node (PIN) set; nodes N3 and N4 as a whole is
another PIN set. Likewise, putatively identical edge
(PIE) set is determined in a similar manner. Edges X1
and X2 as a whole is a PIE set.
To generate a merged model containing non-redundant
information, PINT preserves only one node/edge from
each PIN/PIE set when integrating models (Figure 1B,
deleted nodes and edges are indicated by red crosses).
Finally, to reconstruct inter-pathway links, PINT recur-
sively relocates the end of each edge that was connected to
each discarded node, to respectively identical node
preserved in a merged model (see Figure 1B, edge X4 is
replaced by edge X5). Thus, initially unlinked pathway
models can be re-connected via relocated edges.
Handling pathways-integration exceptions
In the process of BPI, various types of exceptions can
occur, which may or may not be handled by PINT. In
the following subsections, we show three situations that
may cause exceptions and describe how PINT manages
them.
Integrating pathways containing edges of inconsistent
annotation of directionality. It is possible that in one
model of a metabolic pathway a reaction is annotated as
reversible (i.e. bi-directional edge), whereas in other
models the counterpart reaction is annotated as irrevers-
ible (i.e. one-directional edge). If only a stringent rule of
pathways integration were applied, such annotation in-
consistency can lead to redundant edges between nodes
in the merged model. Thus, PINT has been implemented
with two additional rules to handle reaction directionality:
(i) if an edge in one model is one-directional and its coun-
terpart in another model is bi-directional, then in the
merged model this edge will be assigned as bi-directional;
(ii) if an edge in one model is one-directional and its coun-
terpart in another model is also one-directional but in the
Nucleic AcidsResearch, 2010, Vol.38, WebServer issue W125opposite direction, then in the merged model both edges
will be preserved.
In the ﬁrst rule, PINT trusts that a bi-directional edge
represents a reversible reaction and assumes that its
one-directional counterpart in other models is the result
of insuﬃcient annotation. In the second rule, PINT
assumes that the two counterparts in opposite directions
are likely to represent two distinct reactions, each
catalyzed by an exclusive enzyme. Unfortunately, these
rules for handling directionality may still result in errors
in merged models if these assumptions are violated. Thus,
users are advised to make sure that the private models
they have uploaded contain well-curated information
about the directionality of metabolic reactions.
Integrating pathways containing insuﬃcient properties of
entities. When a model annotated with insuﬃcient com-
partment and modiﬁcation information is integrated
with a well-annotated model, the merged model of them
may contain some redundant nodes that cannot be
removed. Incorporating more annotations to an insuﬃ-
cient model can be a good solution, but may require
considerably more eﬀorts for literature review, model
editing, etc.
Thus, PINT was also implemented with a tolerant inte-
gration mode, which may facilitate users to determine
whether it is worth creating a better-annotated model to
perform a more sensible BPI. The tolerant mode can
integrate pathway models in a less stringent way, which
ignores entity compartment and modiﬁcation informa-
tion. In other words, if models are integrated in this
way, the consistency of entity modiﬁcation and/or com-
partment information will not be taken into consideration
when determining the PIN sets as described above
(Figure 1A and B and relevant text in Section The
pathways integration rule). Although this operation may
not generate a decently merged model, it can be used as a
quick and dirty approach to instantly generate a vague but
informative picture about how much crosstalk there might
be among distinct pathways.
Integrating process-diagram models with entity-
relationship-diagram models. Process diagram (PD) and
entity relationship diagram (ERD) are two diﬀerent
notation styles to present pathways diagrammatically.
Each of them has its unique advantages and attracts its
own supporters owing to diﬀerential reasons (15). One
concern is that a model speciﬁcally edited to be displayed
in a PD style may contain temporal sequence of biological
events (16), which an ERD compliant model usually lacks.
Therefore, the aforementioned stringent rule used by
PINT does not instantly suﬃce to integrate an ERD com-
pliant model with a PD compliant one. Integrating only
models exclusively in PD or ERD can be one quick and
clean measure, at the cost of losing invaluable information
in the models already excluded for one round of BPI.
Figure 1. The PINT pathways-integration process. (A) and (B) are the general rules with which PINT performs pathways-integration process. (C)i s
a process diagram and (D) is an entity relationship diagram, where both are considered to be equivalent by PINT.
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PINT to partially address this issue, without claiming
that this PINT has provided a good solution. In the
long run, we believe that a uniﬁed pathway notation
style should be used instead, suggested by Le Novere
et al. (15). Besides, this trick works only for diagrammatic
preview in PINT, both types of notation will be preserved
in the merged models exported from PINT, and users may
further use SBML editors to resolve such inconsistency
issues.
In an ERD compliant model, the state-transition infor-
mation is usually excluded. For instance, in Figure 1D, the
previous state of MAP2K1 is not found in this ERD,
whereas such a piece of information is available in the
PD as in Figure 1C. PINT uses the following steps to
decide how to integrate such an ERD model with a PD
model.
First, for each ERD model, PINT will take the follow-
ing steps: (i) ﬁnding each edge that connects two nodes
containing diﬀerent entities; (ii) labeling each such edge
as an ‘undetermined modulation’ (UM); (iii) labeling
each node upstream/downstream of an UM as a function-
ally ‘undetermined upstream/downstream reactant’
(UUR/UDR). Second, for each PD model, PINT will
look for the state transition information relevant to each
UM, UUR and UDR.
An UUR may be a catalyst, an enhancer, an inhibitor
or a subunit of a complex. An UDR usually corresponds
to a product, whereas the reactant, namely the previous
state of an UDR, is usually omitted in an ERD compliant
model. For instance, in Figure 1D, ‘MAP3K1T-1402ph;
T-1414 ph’ is an UUR; ‘MAP2K1S-218ph; S-222 ph’ is
an UDR; the arrow between the UUR and UDR corres-
ponds to an UM. When this ERD compliant model is
integrated with the PD compliant model (Figure 1C),
PINT can now decide that the UUR catalyzes the phos-
phorylation of the previous state of the UDR. In this case,
PINT will consider that the two models are biologically
equivalent and thus the merged model will be exactly the
same as that shown in the PD (Figure 1C). Otherwise, if
PD compliant models do not have the information that
can compensate the insuﬃciency of an ERD compliant
model, the relation of UM, UUR and UDR will be kept
unchanged in the merged model.
The online annotation editor (for uploading SBML ﬁles
only). In addition to the public pathway models, PINT
users are allowed to upload and use their private models
to perform pathways integration. However, such models
are not necessarily annotated in a manner directly suitable
for BPI. For instance, it is not uncommon that one protein
is annotated with various synonyms in diﬀerent models
(e.g. both HER2 and ERBB2 correspond to the same
protein); one generic name used in diﬀerent models may
actually refer to diﬀerent proteins (e.g. BMP can be
BMP2A, BMP2B, BMP3, etc.). The non-unique naming
of entities in pathway models may make PINT fail to ﬁnd
correct inter-pathway linkers—the very ﬁrst step in BPI.
Besides, using curated models downloaded from
public-domain databases does not necessarily generate
an error-free merged model. For instance, in the curated
models provided by BioModels, phosphorylation of
proteins across diﬀerent models can be represented as
suﬃxes to protein symbols in a variety of styles (e.g.
‘_p’, ‘-PT’, ‘-PY’, ‘-p’, etc.). Redundant nodes containing
entities annotated in such inconsistent styles cannot be
properly removed in BPI.
The PINT online annotation editor was hence de-
signed to assist users to revise the inaccurate and/or
insuﬃcient entity annotations contained in an uploaded
SBML model. The online editor tabulates the mapping
between each node and its re-annotation suggested by
PINT (Supplementary Figure S1A). The re-annotation is
gene symbol-based, and is more intuitive for bench biolo-
gists to conceive than an accession number-based
mapping. Internally, in this automatic re-annotation
process, PINT maps each entity name that may be a
synonym to its approved symbol based on the lookup
tables downloaded from HGNC (17) and ChEBI (18).
When there is one-to-many relationship between a
synonym and a set of candidate symbols, PINT returns
the most probable one with the aid of the internal ‘fre-
quently used synonym’ versus ‘most probable approved
symbol’ lookup table. We prepared this table through
manually analyzing the human pathway models in
BioModels (1).
Thus, each gene or gene product entity is re-annotated
with a HGNC-approved gene symbol (17), its molecular
type (e.g. DNA, RNA and protein), and its modiﬁcations
if available (Supplementary Figure S1A). If an entity rep-
resents a small molecule such as water, ATP, GDP, etc., it
will be re-annotated with a ChEBI-approved symbol (18).
The case shown in Supplementary Figure S1A is about the
PINT re-annotation of a node named Ras-GDP. In this
node, there are two entities, a protein and a small
molecule, which have been correctly re-annotated as
HRAS (type: PROTEIN) and GDP (type:
SIMPLE_MOLECULE) by PINT (Supplementary
Figure S1A). Then users may accept the re-annotation
or revise it again. To save users’ eﬀorts in repetitively
updating the entity properties of multiple occurrences of
one entity in a model, PINT provides a replace-
all-identical-synonym function. When users click the
‘Edit’ button as shown in Supplementary Figure S1A,
they will see a pop-up window like the one in
Supplementary Figure S1B. Any changes of the properties
made in this window can trigger the PINT online editor to
replace the annotations of all its identical entities in this
model being edited. On the other hand, if users do not
want to perform a replace-all operation, they may
instead choose to modify the properties of a particular
occurrence of an entity in the textarea as shown in
Supplementary Figure S1A.
Once the symbol of a protein entity in a human pathway
model is changed by users, its annotation will also be
updated with a new UniProt accession number corres-
ponding to the new symbol. Although this internal
property is invisible to users, it will be included in the
SBML ﬁle of this model exported by PINT. This
measure is to make a PINT-generated model provide in-
formation as suggested by MIRIAM (14).
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The PINT website provides an integrated environment for
users to perform the functions that are required for BPI.
The system ﬂow is presented in Figure 2. On the PINT
web interface, these functions are categorized into four
web pages: Start, Upload, Browse and Workbench (see
the menu bar items on the PINT web pages). Users may
search for pathway models to start with, upload private
pathway models or gene-symbol lists (for highlighting
entities on merged diagrams), browse available models in
PINT, and select pathway models to perform the core BPI
functions, respectively. Uploaded models and gene-
symbol lists will be cached in PINT temporarily and be
cleaned every Saturday night.
The PINT public models and users’ private models. PINT
provides 190 human pathway models for new users to
try BPI immediately (Figure 2, Input layer, PINT public
pathway models). These models were prepared based on
two data sources. First, we used CellDesigner (16) to
re-build 30 human pathway models of the pathway
diagrams provided by BioCarta (http://www.biocarta.
com/). Second, we retrieved 160 human pathway
models through parsing the human pathway information
from the pathway XML ﬁle downloaded from PID (3).
Besides, users can upload their private models into
PINT on the ‘Upload’ page. Pathway models to be
uploaded can be either downloaded from BioModels (1)
or Panther (2), or created by CellDesigner (version 3.5.1 or
later) (16) or SBMLeditor (under implementation) (19).
Besides, every PINT public pathway model can be down-
loaded in the SBML format, and then re-uploaded and
re-annotated as users’ private models. This operation is
useful when integrating pathway models that contain
fusion genes and their products, as demonstrated in an
example on the PINT ‘Documentation’ page.
Selecting pathway models. Both the public and private
pathway models already in PINT can be browsed or
searched by users (Figure 2, Input layer). The PINT
‘Browse’ page lists alphabetically the public and private
pathway models respectively. Besides, the PINT ‘Start’
Figure 2. System ﬂow of PINT. *Users can re-upload the SBML ﬁle exported from PINT. **PINT will accept the SBML ﬁles generated by
SBMLeditor.
1A gene list and fold change ﬁle should follow a particular format (Supplementary Figures S11 and S13).
2Tissue information was
retrieved from UniGene (Build 221) (http://www.ncbi.nlm.nih.gov/unigene).
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may type in keywords (e.g. gene symbol, synonym), or
upload a long list of keywords. Users may also search
for reactions involving a user-speciﬁed entity. This
reaction-search function, very similar to the PID-style
query (3), allows users to take an entity as the ‘center
point’ to wander along relevant reactions further upward
or downward, and thus enables users to quickly ﬁnd
upstream and downstream pathway models. From the
result returned by PINT after a ‘search’ or ‘browse’ oper-
ation, users may choose and send pathway models to the
PINT Workbench to perform BPI.
Integrating pathway models (PINT Workbench). The
PINT Workbench (Figure 2, Workbench layer) provides
the core BPI functions that allow users to visualize
pairwise relations among pathway models, choose a
subset of them for integration, visualize the merged
diagram, highlight entities on the merged diagram and
download the merged model for reuse in PINT or other
SBML model editing/visualization tools (Figure 2, Output
layer).
Relation graph. The core BPI functions of PINT can be
activated if a number of pathway models have been
submitted to the Workbench (see the previous section
‘Selecting pathway models’). On the activated
Workbench, there are a Relation graph, a list of pathway
models, and options to display or export a merged model.
The Relation graph shows the pairwise relations among
the models listed in the PINT Workbench (for an example,
see Supplementary Figure S6). Each number in this graph
is to indicate how many nodes two potentially linkable
pathway models have in common. When a number is
clicked, PINT can generate a merged diagram of two
relevant models for preview, where identical nodes
commonly found in both models are shaded in yellow
[Figure 2, Output layer, the merged diagram (preview)].
Users may thus decide whether such a merged model can
be interesting or not, and choose relevant distinct models
for integration at a later stage.
Highlighting entities on a merged diagram (Painting, PINT
Workbench). The BPI conducted by PINT relies on
putatively identical nodes (PIN) sets (see section
‘The pathways integration rule’), but not on any gene or
protein expression data. This means that merged models
so generated are just hypothetical and may need further
experimental evidence to support their biological signiﬁ-
cance. Therefore, PINT provides a ‘painting’ function that
can highlight entities based on users’ gene-symbol lists
(for the sample format see Supplementary Figure S11),
expression data or the tissue/histology information
(Supplementary Figure S5, S8–S10) retrieved from
UniGene (http://www.ncbi.nlm.nih.gov/unigene). This
function can not only assist users to explore if their
experimental data are consistent with a merged model
but also help users to determine if a merged model
makes biological sense. For instance, one approach to
assess the biological role of a merged model is to highlight
entities with the tissue/histology information. If on a
merged pathway diagram there are more entities expressed
in a cancer tissue (highlighted in red) than in the normal
tissue (highlighted in green), perhaps the pathway repre-
sented by this merged model is implicated with this cancer.
Thus, based on painted diagrams, bench biologists may
use their expertise to decide whether the hypothetical
pathway represented by a merged model is interesting,
and therefore design more experiments to investigate its
features. Alternatively, they may decide to try other com-
binations of models to perform another round of
pathways integration and see if experimental evidence
can support other merged models.
In addition to what is described above, the diagram
painting function can be used to highlight entities in
other biological context, such as selective pressure in evo-
lution. To show this application, PINT provides the gene
list containing the Ka/Ks values of human-mouse
orthologous gene pairs (Supplementary Figure S12,
‘[single click] to upload Ka/Ks values...’). PINT can use
these values to render nodes in the heatmap color scheme
in pathway diagrams. Besides, users may also prepare
their own gene lists that suit their research interests (for
the sample format see Supplementary Figure S13).
An example case
Here, we present an example about how to use PINT to
integrate three models of the RacCycD, Her2 and Ras
pathways. The Ras pathway is about how Ras protein is
involved in the inhibition of cell apoptosis (20). The Her2
pathway is about how Her2 protein is involved in the sig-
naling related to cell growth and diﬀerentiation (21). The
RacCycD pathway is about how Rac and CycD proteins
are involved in the G1/S transition in the cell cycle (22).
Since Her2 protein plays an important role in breast
cancer (23), it is interesting to know how these three
pathways may interact with each other to control cell
growth and anti-apoptosis in breast cancer.
We used CellDesigner to re-build the three pathway
models based on the diagrams provided by BioCarta
(http://www.biocarta.com/) and then converted these
three models into the SBML format. To generate a clear
merged diagram for demonstration only, we have trimmed
these models by taking out certain nodes. Besides, the
entities in the ‘cell membrane and peripheral region’ com-
partment were moved into the ‘Cytosol’ compartment in
order to reduce the number of compartments that will be
displayed in a diagram. Users may download these models
from NAR online (Supplementary data, RacCycd.xml,
her2.xml, ras.xml). Figures S2–S10 in the Supplementary
Data show the screenshots of the step-by-step procedures
to upload these pathway models (Figures S2–S5), display
the merged diagram for preview (Figures S6 and S7), high-
light entities with their tissue/histology information on
the merged diagram of the three pathway models
(Figures S8 and S9), and list the detailed node information
(Figure S10) for one node in this merged diagram.
This application not only eliminated the tedious manual
drawing, but also generated a downloadable model for
users. When this model is re-uploaded to PINT, all the
annotations such as related reactions, external links, etc.
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provides basic functions for both computational and ex-
perimental biologists to come up creative application
scenarios.
DISCUSSION
PINT can integrate only pathway models that are SBML
compatible, which must contain annotation about the role
(reactant, product or catalyst) of each protein entity. Even
though a complex can be an entity in PINT, this tool is not
designed to integrate other biological networks in which
the aforementioned annotations are unavailable. A typical
example of such network is the high-throughput data of
protein–protein interactions. Nevertheless, PINT is able to
integrate diﬀerent types of pathways from diﬀerent
organisms.
Although the pathways collected in PINT are human
pathways, this tool may also integrate private pathway
models from other organisms. As long as the entities are
named consistently, PINT will be able to merge entities
together. For example, EC number can be used as an
entity name and can be merged correctly. The names of
small molecules will be converted to the ChEBI names
based on the alias tables from both KEGG and ChEBI.
However, PINT cannot provide annotation to entities
from other organisms at the present time.
To integrate the cross-species models, users need to
have their own convention to name entities, such as the
EC number. In this case, PINT may generate a reference
map from the pathways in diﬀerent species. Similarly, the
pathways in diﬀerent tissues of a given organism can be
integrated. The ‘painting’ function can be used to label
given entities on the reference map. These entities can be
proteins from a given species, a given tissue or a given
expression status at a given time point.
Taken together, PINT will be a useful tool not only in
studying the regulatory circuit in a given cell/tissue types,
but also in viewing the changes of pathway ﬂux when
dynamic information is available. Moreover, PINT can
also be used to integrate models across states (e.g. diﬀerent
environments) or even across organisms (e.g. in a
metagenomic context). In the latter case, the pathways
across dependent species in diﬀerent environments (24)
can be explored.
FUTURE WORK
Currently, PINT does not support the integration of
distinct kinetic equations that are contained in diﬀerent
models. We are working on ﬁnding useful guidelines to
allow PINT to integrate such equations. Besides, the
SBML models generated by PINT contain modiﬁcation
information that cannot be properly parsed by other
SBML editors. We are discussing a revised format to
resolve this issue.
SUMMARY
Since there are still many unknown details in biological
networks, there will be updates to the current pathway
models in the future. Biological pathway building and
curation are an important step toward assembling a com-
prehensive picture of the networks. During this process,
Biologists may need to try many combinations of avail-
able pathway models and to clarify if their experimental
results ﬁt a new merged model built on existing models.
Therefore, biologists need ﬂexible and user-friendly tools
to assist them to go through the complex process and
PINT was thus designed for this purpose.
AVAILABILITY
The web server of PINT is freely available at http://csb2
.ym.edu.tw/pint/.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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